12 March 2018 - Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.

Having rejected the drug’s for relapsed or refractory classical Hodgkin lymphoma in adults unable to have an autologous stem cell transplant who failed treatment with brentuximab vedotin, the National Institute for Health and Care Excellence is still considering whether it can be used in patients who have had both the transplant and prior treatment.

However, the appraisal committee has requested that the company provides a cost-comparison with Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab), which is approved by NICE in this setting, to help better inform its decision.

Read Pharma Times article